论文部分内容阅读
目的观察雾化吸入重组人干扰素α1b联合更昔洛韦治疗传染性单核细胞增多症的临床效果。方法选取医院收治的传染性单核细胞增多症患儿68例为研究对象,随机分为观察组和对照组,每组34例。对照组给予更昔洛韦治疗,观察组给予雾化吸入重组人干扰素α1b联合更昔洛韦治疗,观察2组患者临床疗效、各临床症状体征恢复正常时间及不良反应发生情况。结果观察组总有效率为91.18%,高于对照组的73.53%(P<0.01);观察组在异常淋巴消失时间及退热时间均明显短于对照组(P<0.01);2组不良反应比较,差异无统计学意义(P>0.05)。结论临床治疗传染性单核细胞增多症可采用雾化吸入重组人干扰素α1b联合更昔洛韦治疗,可缩短异型淋巴细胞消失时间和退热时间,提高治疗效果,不良反应发生率较低,具有较高的临床应用价值。
Objective To observe the clinical effect of inhaled recombinant human interferon α1b combined with ganciclovir in the treatment of infectious mononucleosis. Methods Sixty-eight children with infectious mononucleosis admitted to the hospital were selected as study subjects and randomly divided into observation group and control group with 34 cases in each group. The patients in the control group were treated with ganciclovir. The patients in the observation group were treated with nebulized recombinant human interferon alpha 1b and ganciclovir. The clinical efficacy, clinical signs and symptoms recovery time and adverse reactions in the two groups were observed. Results The total effective rate in the observation group was 91.18%, which was significantly higher than that in the control group (73.53%, P <0.01). The observation group had significantly shorter disappearance time and antipyretic time than the control group (P <0.01) The difference was not statistically significant (P> 0.05). Conclusions The clinical treatment of infectious mononucleosis can be treated by atomized inhalation of recombinant human interferon α1b combined with ganciclovir, which can shorten the disappearance time and antipyretic time of allogeneic lymphocytes and improve the therapeutic effect, the incidence of adverse reactions is low, Has a high clinical value.